Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:developedBy |
cancer immunotherapies
|
| gptkbp:focusesOn |
immuno-oncology
|
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Checkmate Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
CMP-001
|
| gptkbp:website |
https://www.checkmatepharma.com/
|
| gptkbp:bfsParent |
gptkb:Keith_Flaherty_(Board_Member)
|
| gptkbp:bfsLayer |
8
|